whatshot

ATNM   $1.81  5.23% Market Closed After Close 1.84 1.66%

Actinium Pharmaceuticals Inc
show_chart Advanced Chart of ATNM
Last Events:

2023-08-09 Trend pattern changed from сужающийся канал to нисходящий клин.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-05 Trend pattern changed from канал to сужающийся канал.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-02 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

Current temperature: 4.08
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 5.80
Mean unverified/preliminary 5.80 / 5.80
Target Price Low / High 2.00 / 9.80
Median / STD DEV 5.00 / 3.01
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell None None
stoch Sell None None
ma20 Sell Sell None
ma50 None None None
ma100 Sell Sell None
Candlestick PatternOct. 11, 2024 Three Stars -
ISIN US00507W2061
ceo Mr. Sandesh C. Seth M.B.A., M.S.
Website https://www.actiniumpharma.com
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.